New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,352.05 0.40 +0.03%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 27.3% in FY25, the highest of these ten years. ROE, at 101.2%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE19.1%−1.6%28.6%122.3%145.3%74.5%62.7%48.4%84.3%101.2%
ROIC11.1%7.2%16.0%19.8%20.2%19.3%19.1%15.4%20.4%27.3%

Debt

Net debt is 1.19× a year’s EBITDA. Debt is 1.54× equity, against 5.72× in FY19.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.7×1.2×0.9×5.7×2.8×1.7×1.4×1.7×2.0×1.5×
Net debt / EBITDA0.9×1.6×0.6×2.1×1.7×1.4×1.4×1.9×1.7×1.2×

Cash cycle, in days

Customers pay in 113 days, inventory is held 454 days and suppliers are paid in 178. Cash is tied up for 389 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle223346246229261215240285297389
Days to pay suppliers861169410910783106134140178
Days to be paid82969891103105109121108113

Per share, from FY16

Since FY16, per share: free cash flow has grown 11.8% a year; revenue has grown 15.4% a year; book value has grown 9.28% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×1.2×1.1×1.1×1.5×1.8×1.7×0.2×1.1×2.7×
Revenue1.0×0.9×1.0×1.2×1.3×1.6×1.6×1.9×2.5×3.6×
Book value1.0×0.8×0.8×0.2×0.5×0.8×0.9×0.9×1.2×2.2×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
28.91 0.00 36.97 14.97 24.83 44.99 52.90 102.10 65.93 46.83
Piotroski F-Score
6 4 9 6 6 6 7 5 6 7
Altman Z-Score
3.42 2.75 3.52 3.23 3.57 5.14 6.47 6.99 7.89 8.61
P/S ratio
3.72 4.46 5.53 5.48 6.24 8.85 11.53 15.62 15.44 14.79
P/FCF ratio
18.37 18.00 25.18 29.05 27.75 38.74 56.77 216.52 116.64 86.31
Altman Z″-Score (non-manufacturers)
3.21 2.35 3.03 1.66 2.27 2.17 2.04 1.26 2.26 3.79
Beneish M-Score
(2.62) (3.04) (2.64) (2.52) (2.26) (2.47) (2.58) (2.18) (2.21) (1.91)
P/Operating CF
39.35 51.10 82.09 62.32 84.42 110.77 197.95 (1,708.65) 281.04 299.01
P/B ratio
5.61 7.64 10.90 45.34 26.31 27.37 30.54 49.07 48.72 36.34
EV/Sales
3.83 4.56 5.62 6.07 6.77 9.30 12.02 16.14 16.02 15.34
EV/EBITDA
17.09 25.49 23.47 21.81 22.51 33.33 39.67 68.98 49.20 35.32
EV/FCF
18.92 18.39 25.56 32.13 30.09 40.75 59.19 223.69 121.06 89.46
Current Ratio
1.37 1.32 1.73 1.16 1.40 1.23 1.05 0.94 1.15 1.58
Net Debt/EBITDA
0.90 1.57 0.56 2.09 1.75 1.45 1.45 1.93 1.72 1.19
Debt/Equity
0.73 1.17 0.94 5.72 2.85 1.68 1.37 1.69 2.00 1.54
ROE
19.10% (1.59%) 28.63% 122.26% 145.32% 74.52% 62.67% 48.43% 84.26% 101.16%
ROA
7.36% (0.49%) 7.27% 20.00% 14.42% 11.70% 12.71% 9.23% 14.84% 21.59%
ROIC
11.11% 7.25% 16.01% 19.80% 20.20% 19.29% 19.12% 15.37% 20.39% 27.34%
Return on Tangible Assets
22.14% (1.51%) 19.40% 84.82% 45.33% 45.07% 56.56% 46.18% 49.33% 45.79%
Average Days of Receivables
81.98 96.16 98.10 90.62 103.06 104.75 109.46 121.26 107.58 112.87
Earnings Yield
3.46% (0.24%) 2.70% 6.68% 4.03% 2.22% 1.89% 0.98% 1.52% 2.14%
Free Cash Flow Yield
5.44% 5.56% 3.97% 3.44% 3.60% 2.58% 1.76% 0.46% 0.86% 1.16%
Free Cash Flow per Share
3.67 4.31 4.20 4.08 5.63 6.68 6.36 0.88 4.18 10.00
Book value per Share
13.30 11.09 10.61 2.90 6.42 10.09 11.95 12.07 15.85 29.57
Free Cash Flow
3,887.40 4,538.80 4,313.90 3,802.70 5,111.70 6,056.10 5,731.40 792.00 3,760.00 8,972.00
EV/EBIT
24.93 45.43 34.16 27.21 27.43 41.45 48.15 85.29 55.95 38.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026